are available in the literature to date. The authors believe this case to be the first serous cystadenoma arising from the uterus that is described in the literature to date. CONCLUSION: Laparoscopic images in this case portray a rare finding of a uterine serous cystadenoma, a pathology that has never before been described in the literature. Uterine sources of pelvic cystic structures should be considered when evaluating a patient with an adnexal mass.
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DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS:
Anne-Marie Carpenter: Nothing to disclose; Demaretta Rush: Nothing to disclose; Nash S. Moawad: Nothing to disclose.
31 Cost and operative outcomes of robotic compared to laparoscopic hysterectomy for larger uteri E. Abi Khalil, G. Moawad, C. Marfori, P. W. Tyan
Obstetrics and Gynecology, George Washington University Hospital, Arlington, VA OBJECTIVES: Compare operative cost and outcomes between robotic and laparoscopic hysterectomy for larger uteri. MATERIALS AND METHODS: Retrospective cohort study at an academic university hospital including patients undergoing hysterectomy for benign disease between January 2014 and December 2015 by expert minimally invasive surgeons. RESULTS: A total of 196 hysterectomies were identified with 50 cases with uteri larger than 750 gm. Demographic and surgical characteristics were statistically equivalent. Robotic group had a higher body mass index (AE SD) (32.9 AE 6.5 versus 30.4 AE 7.1, p ¼ 0.012) and more frequent history of adnexal surgery (12.9% versus 4.2%, p ¼ 0.031). Laparoscopic group had a higher number of concurrent salpingectomy (81% versus 66.3%, p ¼ 0.02). Estimated blood loss did not differ between procedures. Mean operative time difference between robotic and laparoscopic hysterectomy in uteri between 750 and 1000 g and in uteri >1000 g was 81.3 min (CI ¼ 51.3-111.3, p < 0.0001) and 70 min (CI ¼ 26-114, p < 0.005) respectively, in favor of the robotic group. Mean direct cost difference in uteri between 750 and 1000 g and uteri >1000 g was $1859 (CI ¼ 629-3090, p < 0.006) and $4509 (CI ¼ 377-8641, p < 0.004) respectively, also in favor of the robotic group. CONCLUSION: In expert hands, robotic hysterectomy for larger uteri may be associated with shorter operative time and improved cost profile.
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MATERIALS AND METHODS:
This was a retrospective cohort study of PTNS treatment success and patient acceptance. After IRB approval, records of women were included if they had undergone at least one PTNS treatment for overactive bladder syndrome (OAB) within the study timeframe (November 2013 -March 2016 . The therapy consisted of 12 weekly treatment visits followed by monthly maintenance visits if the patient deemed the therapy helpful. After treatment data were collected, patients were identified as satisfied, unsatisfied, or undecided, based on response to PTNS, as recorded from their visit summary. RESULTS: Data from 34 women were included. On average, patients were 70.2 (AESD, 12) years of age, had a BMI of 29.9 (AE8.9) kg/m 2 , and traveled 11.2 (AE12.3) miles to receive PTNS treatments. Overall, 22 patients (64.7%) were determined to be satisfied, 4 (11.8%) unsatisfied, and 8 (23.5%) undecided. Satisfied patients completed an average of 10.9 treatments (AE2.4), those who were unsatisfied completed an average of 9.5 (AE2.6), and those left undecided completed an average of 7.2 (AE4.3). The fourth treatment visit was the most likely to predict whether a patient would be satisfied by the last (12th) treatment. Based on patient recall, comparing the number of voids per day with the number of treatment visits, no clear trend emerged. Only one minor adverse event was noted during the study. CONCLUSION: Overall, the success of the PTNS therapy was high, at 64.7%, consistent with previous studies. Although patients may be discouraged or unsure of treatment effectiveness at first, results from this small sample suggest that they can be told not to expect results until the fourth treatment.
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